Masayoshi Yasui1, Toshimasa Tsujinaka2, Masaki Mori3, Tsuyoshi Takahashi3, Yasuo Nakashima4, Toshirou Nishida5. 1. Department of Gastroenterological Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Nakamichi 1-3-3, Higashinari-ku, Osaka, Osaka, 537-8511, Japan. myasui-gi@umin.ac.jp. 2. Department of Surgery, Kaizuka City Hospital, Hori 3-10-20, Kaizuka, Osaka, 597-0015, Japan. 3. Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Yamadaoka 2-2(E2), Suita, Osaka, 565-0871, Japan. 4. Department of Surgery, Osaka Red Cross Hospital, Fudegasaki-cho 5-30, Tennoji-ku, Osaka, Osaka, 543-8555, Japan. 5. National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-Ku, Tokyo, 104-0045, Japan.
Abstract
PURPOSE: Rectal gastrointestinal stromal tumors (GISTs) are rare. Accordingly, their clinical features are not well-documented and optimal treatment has not been established. The objective of this study is to clarify the rates and patterns of recurrence after surgical resection of rectal GISTs, with a focus on outcomes and therapeutic modalities. METHODS: The registry was designed to collect data on rectal GISTs recorded between January, 2003 and December, 2007 at 40 participating institutions of the Kinki GIST Study Group. The principal variables were the rates and patterns of recurrence of rectal GISTs. Other study variables were age, sex, tumor size, mitotic count, distance from the anal verge, tumor location, surgical procedures, surgical margins, and recurrence-free survival. RESULTS: Twenty-four cases were registered, 11 (45.8%) of which were classified as high-risk by the modified NIH criteria. Locoregional recurrence (7/23, 30.4%) was the predominant recurrence pattern after curative resection, with rates that did not differ after local excision (33.3%; 3/9) vs. extended resection (28.6%; 4/14). The recurrence rates were high (25.0%) even for patients with low-risk disease. There was only one case of recurrence among patients who received perioperative treatment with imatinib. CONCLUSIONS: Rectal GISTs showed high rates of local recurrence regardless of the surgical procedure. Perioperative treatment with imatinib may improve outcomes.
PURPOSE:Rectal gastrointestinal stromal tumors (GISTs) are rare. Accordingly, their clinical features are not well-documented and optimal treatment has not been established. The objective of this study is to clarify the rates and patterns of recurrence after surgical resection of rectal GISTs, with a focus on outcomes and therapeutic modalities. METHODS: The registry was designed to collect data on rectal GISTs recorded between January, 2003 and December, 2007 at 40 participating institutions of the Kinki GIST Study Group. The principal variables were the rates and patterns of recurrence of rectal GISTs. Other study variables were age, sex, tumor size, mitotic count, distance from the anal verge, tumor location, surgical procedures, surgical margins, and recurrence-free survival. RESULTS: Twenty-four cases were registered, 11 (45.8%) of which were classified as high-risk by the modified NIH criteria. Locoregional recurrence (7/23, 30.4%) was the predominant recurrence pattern after curative resection, with rates that did not differ after local excision (33.3%; 3/9) vs. extended resection (28.6%; 4/14). The recurrence rates were high (25.0%) even for patients with low-risk disease. There was only one case of recurrence among patients who received perioperative treatment with imatinib. CONCLUSIONS: Rectal GISTs showed high rates of local recurrence regardless of the surgical procedure. Perioperative treatment with imatinib may improve outcomes.
Authors: Dian Wang; Qiang Zhang; Charles D Blanke; George D Demetri; Michael C Heinrich; James C Watson; John P Hoffman; Scott Okuno; John M Kane; Margaret von Mehren; Burton L Eisenberg Journal: Ann Surg Oncol Date: 2011-12-28 Impact factor: 5.344
Authors: Suzanne George; Qian Wang; Michael C Heinrich; Christopher L Corless; Meijun Zhu; James E Butrynski; Jeffrey A Morgan; Andrew J Wagner; Edwin Choy; William D Tap; Jeffrey T Yap; Annick D Van den Abbeele; Judith B Manola; Sarah M Solomon; Jonathan A Fletcher; Margaret von Mehren; George D Demetri Journal: J Clin Oncol Date: 2012-05-21 Impact factor: 44.544
Authors: Piotr Rutkowski; Alessandro Gronchi; Peter Hohenberger; Sylvie Bonvalot; Patrick Schöffski; Sebastian Bauer; Elena Fumagalli; Pawel Nyckowski; Buu-Phuc Nguyen; Jan Martijn Kerst; Marco Fiore; Elzbieta Bylina; Mathias Hoiczyk; Annemieke Cats; Paolo G Casali; Axel Le Cesne; Jürgen Treckmann; Eberhard Stoeckle; Johannes H W de Wilt; Stefan Sleijfer; Ronald Tielen; Winette van der Graaf; Cornelis Verhoef; Frits van Coevorden Journal: Ann Surg Oncol Date: 2013-06-13 Impact factor: 5.344
Authors: David D B Bates; Maria Clara Fernandes de Paula; Natally Horvat; Shannon Sheedy; Chandana Lall; Zahra Kassam; Perry Pickhardt; Neeraj Lalwani; Dhakshinamoorthy Ganeshan; Iva Petkovska Journal: Abdom Radiol (NY) Date: 2019-11
Authors: Chinock Cheong; Jeonghyun Kang; Byung Soh Min; Nam Kyu Kim; Joong Bae Ahn; Kang Young Lee Journal: PLoS One Date: 2022-09-09 Impact factor: 3.752
Authors: Henrik Ghantarchyan; Tyrell Daniel; Manrique A Guerrero; John Perrone; Paul Hanna; Jamshed Zuberi; Derick J Christian Journal: Int J Surg Case Rep Date: 2020-08-29